Bethan Freestone
Consultant, Clinical Lead
Dr Bethan Freestone is a consultant and clinical lead at University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
BCIS ACI 2020: Treating Shock in 2020
Published: 07 March 2020
-
Views:
138
-
Likes:
1
Overview
Full programme
Overview
This video series filmed at the BCIS ACI 2020 meeting features an expert panel who examine the issues around treating shock and PPCI, they discuss the treatment options and the future and consider if mechanical circulatory support can be used as a way forward.
This video series was created in partnership with BCIS.
Educational Objectives
- To consider the prevalence and burden of shock in contemporary practice
- To review the literature and data around treatment for shock patients
- To discuss best practice treatment strategy for shock patients
- To debate whether dedicated centres could improve outcomes
- To discuss upcoming clinical data that may improve decision making.
Series overview
Part 1
Prevalence of Shock and Outcomes in PPCI
Dr Bethan Freestone (Birmingham Heartlands Hospital, Birmingham, UK), chair of the roundtable, introduces the topic of cardiogenic shock. Professor Anthony Gershlick (University of Leicester, Leicester, UK) discusses the prevalence of the condition and viable treatment options.
1 session
Prevalence of shock and outcomes in PPCI
Watch now
Part 2
How Should We Treat Shock?
Dr Bethan Freestone (Birmingham Heartlands Hospital, Birmingham, UK) poses the question: How would you treat your cardiogenic shock patient? Prof Keith Oldroyd (West of Scotland Regional Heart & Lung Centre and Golden Jubilee National Hospital, Glasgow, UK) discusses treatment options based on his experiences. Dr Farzin Fath-Ordoubadi (Manchester University NHS, Manchester, UK) reflects on the role of drug therapy. Prof Anthony Gershlick (University of Leicester, Leicester, UK) talks about the need for smart medicine.
1 session
How Should We Treat Shock?
Watch now
Part 3
Is MCS the Way Forward?
Dr Bethan Freestone (Birmingham Heartlands Hospital, Birmingham, UK) invites the panel to discuss the pros and cons of mechanical support devices. Dr Farzin Fath-Ordoubadi (Manchester University NHS, Manchester, UK) discusses the available devices and choosing the right time to use them. Prof Keith Oldroyd (West of Scotland Regional Heart & Lung Centre and Golden Jubilee National Hospital, Glasgow, UK) and Prof Anthony Gershlick (University of Leicester, Leicester, UK) talk about the challenges of conducting cardiogenic shock trials and the need for established centres.
1 session
Is MCS the Way Forward?
Watch now
Part 4
What’s on the Horizon?
The panel concludes the roundtable with exploring what studies are needed to help decision making. Dr Farzin Fath-Ordoubadi (Manchester University NHS, Manchester, UK) talks about DanGer shock. Prof Anthony Gershlick (University of Leicester, Leicester, UK) shares his experiences with the EURO SHOCK trial. The study focuses on the early use of a mechanical support device (ECMO), that can support patients and their heart needs to recover from a severe heart attack.
1 session
What’s on the Horizon?
Watch now
Faculty biographies
Anthony H Gershlick
Anthony Gershlick, Consultant Cardiologist at Leicester’s Hospitals and Honorary Professor of Interventional Cardiology at the University of Leicester.
Farzin Fath-Ordoubadi
Farzin Fath-Ordoubadi is a consultant interventional cardiologist based at Manchester Heart Centre, Manchester Royal Infirmary, Manchester, UK.
Keith G Oldroyd
Clinical Director of Cardiology
Professor Keith G Oldroyd MBChB; MD(Hons); FRCP(Glasg); FSCAI is a Consultant Interventional Cardiologist at the West of Scotland Regional Heart and Lung Centre in the Golden Jubilee National Hospital. He holds a personal chair within the Institute of Cardiovascular and Medical Sciences, University of Glasgow. He qualified in medicine from the University of Aberdeen in 1982.
In 2007 he became the first Clinical Director of Cardiology at the newly created West of Scotland Regional Heart and Lung Centre. From 2011-2014 he was also Director of R&D and currently he leads on CV research for NHS Scotland. His own research interests include the clinical and experimental assessment of novel drug eluting stents and the use of invasive physiological indices of stenosis severity to guide decision making in the cath lab. He has been a principal investigator in several international trials including FAME, FAME 2, PRAMI and LEADERS FREE, all of which have been published in the New…
